Gilead Sciences, Inc. (GILD )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol GILD
- Company Gilead Sciences, Inc.
- Price $133.48
- Changes Percentage 0.6
- Change 0.79
- Day Low $131.89
- Day High $133.98
- Year High $157.29
- Year Low $95.3
- Market Cap $165,678,045,600
- Price Avg 50 EMA (D) $139.96
- Price Avg 200 EMA (D) $126.92
- Exchange NASDAQ
- Volume 5,957,306
- Average Volume 6,356,727
- Open $132.92
- Previous Close $132.69
- EPS 8.15
- PE 16.38
- Earnings Announcement 2026-05-07 20:00:00
- Shares Outstanding $1,241,220,000
Company brief: GILEAD SCIENCES, INC. (GILD )
- Healthcare
- Drug Manufacturers - General
- Mr. Daniel P. O'Day
- https://www.gilead.com
- US
- N/A
- 01-22-1992
- US3755581036
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD Corporation News
Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF
businesswire.com -- LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--Gilead's Earnings per Share Expected to Be Up 52% as Florida's and other States' AIDS Drug Programs Falters, says AHF....
Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain
reuters.com -- Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has climbed since its June launch, but U.S. health providers say not all patients are interested in the new option a...
Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
zacks.com -- Get a deeper insight into the potential performance of Gilead (GILD) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some o...
Can You Sue A Drug Company For Not Inventing Faster?
forbes.com -- This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science....
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
zacks.com -- Gilead Sciences gears up for Q1 earnings with HIV drugs driving growth, but cell therapy headwinds and rising costs could shape the outlook....